PT  - JOURNAL ARTICLE
AU  - Olga N. Brodskaya
AU  - Alexandra A. Ball
AU  - Marina S. Kevorkova
AU  - Daria D. Glazova
TI  - Risk factors for parapneumonic effusion in community-asquired pneumonia
AID  - 10.1183/13993003.congress-2019.PA3848
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA3848
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA3848.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA3848.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - 20–40% of patients hospitalized for community-acquired pneumonia develop parapneumonic effusion.Aim: to identify factors associated with development of parapneumonic effusion in hospitalized patients with community-acquired pneumonia.Methods: case control study. From 499 patients with community-acquired pneumonia hospitalized at the Pulmonary Department of Moscow Hospital in 2017 year, 74 developed parapneumonic effusion (14,82%). The case group is 60 patients with community-acquired pneumonia with parapneumonic effusion with median age of 58 years (47.25-74), 34 male. The matched control group is 60 patients with community-acquired pneumonia without parapneumonic effusion, median of age 55 years (32.5- 69), 30 male. Exclusion criteria: cancer, tuberculosis, pulmonary embolism. 14 patients were excluded. Statistical analysis was performed using the IBM SPSS Statistics 23. Data presents at median (25-75 percentile).Results: Number of days from the onset of the disease to the start of antibiotic therapy was found to differ significantly between the case and control group, 6 days (3-9.5) vs 3.5 days (2-7) (p = 0.042), respectively. The frequency of bilateral pneumonia in the case group was 26.6%, in the control group was11.6% (p <0.05). Patients of the case group have been receiving antibiotic treatment longer than patients from the control group 13,3 days (9.5–17 ) vs 9 days (7–12 ) (p = 0.001), this significantly increased the duration of hospitalization 15.5 days (12-20) vs 11 days (9-14);( p = 0.003).Conclusion: Late prescription of antibiotics may contribute to the development of parapneumonic effusion in patients with community-acquired pneumonia.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA3848.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).